Research Article
Published: 11 October, 2024 | Volume 8 - Issue 1 | Pages: 028-033
The aim of this work is to verify the pharmaceutical form in the galenic field of oral Budesonide compounded used in Crohn’s disease: capsules delay release or oral suspension. In particular ways the kinds of excipients or bases-vehicle used in the galenic pharmacy practice. The therapeutic need for Crohn’s disease requires a release of the API in delayed-release DR. The Budesonide molecule shows low systemic impacts due to its hepatic metabolism vs. a topical effect useful in this pathology. In this work, the oral pharmaceutical forms are analyzed: modified-release capsules and oral suspension with specific advantages for each one. Some formulations provided by various pharmacies are reported in this work as well as new technology like the 3D-PRINTING systems for colonic targeting tablets.
Read Full Article HTML DOI: 10.29328/journal.acgh.1001048 Cite this Article Read Full Article PDF
Budesonide; Crohn's disease; Pediatric; Delay release; Capsules acid resistance filled with HPMC; Metolose; Methocel; Oral suspension; Ready for use vehicle; 3D printing
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."